Trial Profile
A Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study of the Safety, Tolerability and Immunogenicity of Two Doses of a Clostridium Difficile Toxoid Vaccine, Alum Adsorbed, in Healthy Adult Volunteers (18 - 55 Years).
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 26 May 2012
Price :
$35
*
At a glance
- Drugs Clostridium difficile vaccine (Primary)
- Indications Clostridium difficile infections
- Focus Adverse reactions
- Sponsors Sanofi Pasteur Holding
- 14 Nov 2008 New trial record.